Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

RECEIPT OF THE FIRST INSTALMENT OF PROJECT FUNDING UNDER A NATIONAL MAJOR SCIENCE AND TECHNOLOGY PROJECT

AND

OBTAINING ETHICS APPROVAL FROM THE LEAD INSTITUTION FOR THE PHASE III CLINICAL TRIAL OF MT200605

The board of directors (the "**Board**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, the Company and Beijing Tiantan Hospital, Capital Medical University (首都醫科大學附屬北京天壇醫院) ("**Beijing Tiantan Hospital**") are jointly undertaking a research project involving MT200605, a key product of the Company, under the National Major Science and Technology Project for Innovative Drug Development, and the Company has recently received the first instalment of central government funding for the project. The Company has also obtained ethics approval from the lead institution for the Phase III clinical trial of MT200605.

I. BACKGROUND AND PRINCIPAL CONTENT OF THE PROJECT

The research project (the "**Project**") falls under the National Major Science and Technology Project for Innovative Drug Development and is jointly undertaken by the Company and Beijing Tiantan Hospital.

The National Major Science and Technology Project for Innovative Drug Development focuses on major diseases that pose significant threats to public health in China, including malignant tumours, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes and autoimmune diseases. It addresses major scientific and technological challenges in drug research, development and industrialisation, with the aim of developing innovative drugs of significant clinical value and strengthening China's pharmaceutical innovation capabilities.

Beijing Tiantan Hospital is the host institution of the National Clinical Research Center for Neurological Diseases and a principal institution leading clinical research into cerebrovascular diseases in China. Its neurology team has led a number of international multicentre clinical trials in acute ischemic stroke, including TASTE-2, TRACE-III and EMPHASIS, with research findings published in international academic journals, including The New England Journal of Medicine and The Lancet. The hospital is one of the leading institutions in China for clinical research in stroke.

II. SCOPE OF COLLABORATION

Under the Project task document and the collaboration agreement between the parties, the Group is responsible for the research and development, manufacture and supply of MT200605 for clinical trials. The Group will also support the implementation of the clinical trial protocol, undertake quality control and pharmacovigilance activities relating to the investigational product, and ensure the compliant use of Project funding and submission of progress reports.

Beijing Tiantan Hospital is responsible for the academic leadership and design of the clinical trial protocol, organising the multicentre clinical trial network and coordinating trial implementation across participating sites, as well as clinical data collection, statistical analysis and clinical trial quality control, and providing methodological and platform support for the Project through the clinical research methodology department, project management department, and clinical data and biospecimen repository of the National Clinical Research Center for Neurological Diseases.

Intellectual property arising from the Project will be governed by the applicable intellectual property management requirements for national science and technology major projects and the collaboration agreement between the parties.

III. FUNDING ARRANGEMENTS

The Company has recently received the first instalment of central government funding for the Project in the amount of RMB960,000. Under the Project task document, the remaining funding will be disbursed in stages, subject to the satisfactory completion and acceptance of the relevant Project milestones. The first instalment will be used to support the clinical research and development of MT200605.

IV. SIGNIFICANCE TO THE GROUP

The Board believes that the collaboration and receipt of the first instalment of Project funding are of strategic significance to the Group, particularly in the following respects.

1. Advancing the Clinical Development of MT200605

Building on the positive results of the Phase II clinical trial of MT200605, the collaboration is expected to fully utilise Beijing Tiantan Hospital's expertise in stroke research and multicentre clinical trials to support the further clinical development of MT200605. Meanwhile, the Project funding will provide additional financial support for the relevant research and development activities, facilitating the continued clinical development of the product.

2. Enhancing Clinical Development Capabilities and Deepening Research Collaboration

The Group's participation in a national major science and technology project reflects the high degree of alignment between the Company's research and development direction and the national strategy for innovative drug development. The collaboration is expected to further enhance the Group's capabilities in clinical trial management and clinical research, supporting the continued development of its innovative drug pipeline in the field of cardiovascular and cerebrovascular diseases.

V. ETHICS APPROVAL FOR THE PHASE III CLINICAL TRIAL OF MT200605

Following completion of the Phase II clinical trial of MT200605, the Company has received the first instalment of central government funding for the Project and is advancing the clinical development of MT200605 towards Phase III. The Company recently obtained approval from the ethics committee of Beijing Tiantan Hospital, the lead institution for the Phase III clinical trial of MT200605 for the treatment of acute ischemic stroke (the "**Phase III Clinical Trial**"). The approval relates to the Phase III Clinical Trial entitled "A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Study to Confirm the Efficacy and Safety of MT200605 in Patients with Acute Ischemic Stroke" (Protocol No. MT200605-AIS-3041).

VI. RISK WARNING

The research and development of new drugs involves substantial risks and uncertainties. There is no assurance that MT200605 will ultimately be successfully developed and commercialised. Subsequent disbursements of funding for the Project are subject to the relevant milestone and acceptance requirements being met and may not be made as expected if such requirements are not met.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 4 November 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.